FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of...
- The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to...
- MDNA11’s selectivity and dose-dependent stimulation of anti-cancer immune cells indicates potential for increased anti-tumor activity with continued dose escalation...
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular...
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE...
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the...
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients...
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy...
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,...
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271...
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:01 CEST Biocartis Announces Conversion of a Portion of the Convertible Term Loan...
PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:00 CEST Invitation to the Extraordinary Shareholders’ Meeting Mechelen, Belgium, 28 October 2022 –...
BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in...
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...
Only portable hair removal laser system with blended wavelengths for all skin phototypes to be launched at the Fall Clinical...
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with...